ERAP2 and acute lymphoblastic leukemia: Using a potent ERAP2 inhibitor, DG011A, to treat MOLT-4 lymphoblastic leukemia cells for selective ERAP2 inhibition, the study noted that the treatment induced significant shifts in the immunopeptidome.